摘要
目的研究新辅助化疗对宫颈癌患者血清和组织中UPAR、TGF-β、CD105水平的影响及其疗效。方法选取2015年1月~2016年2月间收治的72例宫颈癌患者为研究对象,随机分为对照组(常规放疗)36例和观察组(新辅助化疗联合放疗)36例,比较两组患者的临床总有效率、组织学有效率、治疗前后血清和组织UPAR、TGF-β、CD105的表达情况。结果观察组的临床总有效率及组织学有效率均高于对照组,血清和组织中UPAR、TGF-β、CD105的表达均低于对照组,差异均有统计学意义(P<0.05)。结论新辅助化疗对宫颈癌患者的疗效确切,可显著降低血清及组织中UPAR、TGF-β、CD105的表达,在宫颈癌治疗中具有应用价值。
Objective To study the effect of neoadjuvant chemotherapy on the levels of UPAR, TGF-β and CD105 in serum and tissues of patients with cervical cancer. Methods Between January 2015 and February 2016, 72 patients with cervical cancer in our hospital were selected as the study objects and randomly divided into control group （36 cases） and observation group （36 cases）. Patients in control group received conventional radiotherapy, while patients in observation group received neoadjuvant chemotherapy combined with radiotherapy. The total clinical effective rates, histological effective rates, serum and tissue expression of UPAR, TGF-βand CD105 before and after the treatment of the two groups were compared. Results The total clinical effective rates and histological effective rates of observation group were higher than those of control group. The expression levels of UPAR, TGF-β and CDI05 in serum and tissue of observation group were all lower than those of control group （P〈0.05）. Conclusion The neoadjuvant chemotherapy had definite curative effect in the treatment of cervical cancer patients. It could significantly reduce the expressions of serum and tissue UPAR, TGF-β3 and CD105 in cervical cancer patients. So it had application value in the treatment of cervical cancer.
作者
冯春翠
徐伏兰
周琦
陈辉
FENG Chuncui XU Fulan ZHOU Qi CHEN Hui(Department of Obstetrics and Gynaecology, Xiaogan Central Hospital, Xiaogan, Hubei, 432100, China Department of Gynaecology, Wuhan Union Hospital, Affiliated to Ton~i Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China)
出处
《肿瘤药学》
CAS
2017年第3期319-323,共5页
Anti-Tumor Pharmacy
基金
湖北省自然科学基金(2014CFB996)
